Xiangyu Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiangyu Xu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Bo Wang
Translational Medicine Center, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
1 shared publication Chao Li
Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong University Health Science Centre, Xi'an, China
1 shared publication- Chenchen He
Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
1 shared publication Chenyu Wei
Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
1 shared publicationDan Han
Department of Dermatology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
1 shared publicationDongxia Liang
Department of General Surgery, Second Affiliated Hospital, and Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi’an Jiaotong University, Xi’an, Shaanxi, China
1 shared publication
Latest Publications
- 28 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (873)
Keratinocyte-derived CHI3L2 reprograms phospholipid metabolism to promote skin inflammation in psoriasis
Psoriasis is a chronic inflammatory skin disorder characterized by hyperproliferative keratinocytes and a dysregulated cytokine milieu, perpetuating a self-reinforcing inflammatory cycle. Despite the key involvement of keratinocytes in this pathogenic loop, the molecular pathogenesis remains incompletely understood. Here, we identify chitinase-like protein CHI3L2 as a key mediator. Elevated CHI3L2 levels were detected in serum and lesional skin from patients with psoriasis, predominantly in keratinocytes, as also verified by single-cell RNA sequencing and spatial transcriptomic analyses. In vitro stimulation of keratinocytes with M5 cytokine cocktail (IL-17A, IL-22, oncostatin M, IL-1α, and TNF-α) increased CHI3L2 expression, demonstrating that CHI3L2 is inducible under inflammatory conditions. Transgenic mice expressing human CHI3L2 exhibited aggravated psoriasis-like phenotypes in both imiquimod- and mannan-induced psoriasis models, characterized by epidermal hyperplasia and scaling. To dissect the role of CHI3L2, we used recombinant protein injection, parabiosis, and bone marrow transplantation, identifying keratinocytes as the primary source of pathogenic CHI3L2. This was further confirmed by keratinocyte-specific CHI3L2 knockin mice. CHI3L2 functions in the HaCaT cell line and primary keratinocytes were investigated by recombinant CHI3L2 administration or CHI3L2 knockout. CHI3L2 disrupted phospholipid homeostasis, leading to altered inflammatory responses, proliferation, and differentiation of keratinocytes. CHI3L2 activated secretory phospholipase A2, elevating lysophosphatidylcholine, thereby establishing an autocrine loop perpetuating keratinocyte inflammation and reshaping the immune microenvironment. Therapeutic neutralization of CHI3L2 with antibodies or intervention of phospholipid pathway ameliorated skin inflammation in mouse psoriasis models. Our findings reveal CHI3L2 as an important regulator of keratinocyte-driven lipid remodeling and inflammation in psoriasis, highlighting potential as a therapeutic target.
- 28 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (873)
Keratinocyte-derived CHI3L2 reprograms phospholipid metabolism to promote skin inflammation in psoriasis
Psoriasis is a chronic inflammatory skin disorder characterized by hyperproliferative keratinocytes and a dysregulated cytokine milieu, perpetuating a self-reinforcing inflammatory cycle. Despite the key involvement of keratinocytes in this pathogenic loop, the molecular pathogenesis remains incompletely understood. Here, we identify chitinase-like protein CHI3L2 as a key mediator. Elevated CHI3L2 levels were detected in serum and lesional skin from patients with psoriasis, predominantly in keratinocytes, as also verified by single-cell RNA sequencing and spatial transcriptomic analyses. In vitro stimulation of keratinocytes with M5 cytokine cocktail (IL-17A, IL-22, oncostatin M, IL-1α, and TNF-α) increased CHI3L2 expression, demonstrating that CHI3L2 is inducible under inflammatory conditions. Transgenic mice expressing human CHI3L2 exhibited aggravated psoriasis-like phenotypes in both imiquimod- and mannan-induced psoriasis models, characterized by epidermal hyperplasia and scaling. To dissect the role of CHI3L2, we used recombinant protein injection, parabiosis, and bone marrow transplantation, identifying keratinocytes as the primary source of pathogenic CHI3L2. This was further confirmed by keratinocyte-specific CHI3L2 knockin mice. CHI3L2 functions in the HaCaT cell line and primary keratinocytes were investigated by recombinant CHI3L2 administration or CHI3L2 knockout. CHI3L2 disrupted phospholipid homeostasis, leading to altered inflammatory responses, proliferation, and differentiation of keratinocytes. CHI3L2 activated secretory phospholipase A2, elevating lysophosphatidylcholine, thereby establishing an autocrine loop perpetuating keratinocyte inflammation and reshaping the immune microenvironment. Therapeutic neutralization of CHI3L2 with antibodies or intervention of phospholipid pathway ameliorated skin inflammation in mouse psoriasis models. Our findings reveal CHI3L2 as an important regulator of keratinocyte-driven lipid remodeling and inflammation in psoriasis, highlighting potential as a therapeutic target.
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400605
Time to Benefit of Androgen Deprivation Therapy in Patients With Localized Prostate Cancer Undergoing Radiotherapy
PURPOSE: Combining radiotherapy with androgen deprivation therapy (ADT) is recommended for localized prostate cancer. However, the time required for significant therapeutic benefits is not well quantified. This study aims to determine the time to benefit (TTB) of ADT in these patients. METHODS: We systematically searched PubMed, Scopus, Embase, and Cochrane databases for randomized clinical trials that compared definitive radiotherapy with or without ADT in localized prostate cancer. The primary end point was all-cause mortality. We reconstructed individual patient survival data and calculated TTB using Weibull survival curves, the frequentist method, and the delta method. RESULTS: Eight trials with 6,839 participants were included, with more than 80% of them being patients with intermediate- or high-risk prostate cancer. For patients adding ADT to radiotherapy, it took 7.46 (95% CI, 2.53 to 22.00), 11.36 (95% CI, 4.61 to 28.03), 19.97 (95% CI, 10.03 to 39.78), and 30.90 months (95% CI, 17.90 to 53.36) to prevent one case of all-cause mortality per 1,000, 500, 200, and 100 patients, respectively. To prevent one case of prostate cancer–specific mortality, local progression, distant metastasis, and biochemical failure per 100 patients, it required 40.58 (95% CI, 30.20 to 54.53), 10.92 (95% CI, 6.03 to 19.79), 11.36 (95% CI, 6.55 to 19.69), and 7.80 months (95% CI, 5.14 to 11.83), respectively. CONCLUSION: Adding ADT to radiotherapy provides rapid clinical benefits for patients with intermediate- and high-risk localized prostate cancer. Patients with an expected lifespan over 30 months may benefit from this treatment.
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400605
Time to Benefit of Androgen Deprivation Therapy in Patients With Localized Prostate Cancer Undergoing Radiotherapy
PURPOSE: Combining radiotherapy with androgen deprivation therapy (ADT) is recommended for localized prostate cancer. However, the time required for significant therapeutic benefits is not well quantified. This study aims to determine the time to benefit (TTB) of ADT in these patients. METHODS: We systematically searched PubMed, Scopus, Embase, and Cochrane databases for randomized clinical trials that compared definitive radiotherapy with or without ADT in localized prostate cancer. The primary end point was all-cause mortality. We reconstructed individual patient survival data and calculated TTB using Weibull survival curves, the frequentist method, and the delta method. RESULTS: Eight trials with 6,839 participants were included, with more than 80% of them being patients with intermediate- or high-risk prostate cancer. For patients adding ADT to radiotherapy, it took 7.46 (95% CI, 2.53 to 22.00), 11.36 (95% CI, 4.61 to 28.03), 19.97 (95% CI, 10.03 to 39.78), and 30.90 months (95% CI, 17.90 to 53.36) to prevent one case of all-cause mortality per 1,000, 500, 200, and 100 patients, respectively. To prevent one case of prostate cancer–specific mortality, local progression, distant metastasis, and biochemical failure per 100 patients, it required 40.58 (95% CI, 30.20 to 54.53), 10.92 (95% CI, 6.03 to 19.79), 11.36 (95% CI, 6.55 to 19.69), and 7.80 months (95% CI, 5.14 to 11.83), respectively. CONCLUSION: Adding ADT to radiotherapy provides rapid clinical benefits for patients with intermediate- and high-risk localized prostate cancer. Patients with an expected lifespan over 30 months may benefit from this treatment.